Ferrous gluconate


Concise Prescribing Info
Indications/Uses
Iron-deficiency anaemia.
Dosage/Direction for Use
Adult : PO As elemental Fe: Treatment: 100-200 mg/day in 2-3 divided doses. Prevention: 60 mg/day.
Dosage Details
Oral
Iron-deficiency anaemia
Adult: As elemental Fe: Treatment: 100-200 mg daily in 2-3 divided doses. Prevention: 60 mg daily.
Child: As elemental Fe: Treatment: 3-6 mg/kg daily in 3 divided doses.
Administration
Should be taken on an empty stomach. Best taken on an empty stomach. May be taken w/ meals to reduce GI discomfort.
Contraindications
Haemochromatosis, haemosiderosis, haemoglobinuria, anaemias not caused by Fe deficiency (e.g. thalassaemia), active peptic ulcer, regional enteritis, ulcerative colitis, alcoholism, hepatitis. Patients receiving repeated blood transfusions or parenteral Fe therapy.
Special Precautions
Patient w/ intestinal strictures and diverticular disease, haemolytic anaemia, Fe absorption disorders. Childn. Pregnancy and lactation.
Adverse Reactions
GI: GI discomfort, anorexia, nausea, vomiting, heartburn, constipation or diarrhroea, faecal impaction, dark stools, dental discolouration.
Genitourinary: Urine discolouration.
Dermatologic: Allergic reactions, contact dermatitis.
Patient Counseling Information
This drug may cause black discolouration of the stool.
MonitoringParameters
Monitor serum Fe, total Fe binding capacity, Hb, and reticulocyte count.
Overdosage
Symptoms: Nausea, vomiting, diarrhoea, abdominal pain, haematemesis, rectal bleeding, lethargy and circulatory collapse. Hyperglycaemia, hypotension, tachycardia, and metabolic acidosis may also occur. Management: Administer an emetic then perform gastric lavage w/ desferrioxamine soln 2g/L. This is followed by instillation of desferrioxamine 5 g in 50-100 mL of water in the stomach. Adult patients may be given mannitol or sorbitol to include small bowel emptying. For severe poisoning, when shock and coma are present, give immediate supportive treatment and administer IV infusion of desferrioxamine 15 mg/kg/hr in childn or 5 mg/kg/hr in adults (Max 80 mg/kg/24 hr). In less severe cases, IM desferrioxamine 1 g 4-6 hrly in childn or 50 mg/kg (Max 4 g) in adults may be given.
Drug Interactions
May form a chelate w/ acetohydroxamic acid, resulting in reduced absorption of both drugs. Toxic compounds may be formed w/ concomitant use of dimercaprol. Decreased absorption w/ antacids containing Ca salts, carbonates or Mg trisilicate, and other drugs containing bicarbonates, carbonates, oxalates or phosphates due to formation of less soluble or insoluble complexes. Reduced absorption w/ trientine, cholestyramine, tetracyclines, Zn, PPIs. Increased absorption w/ ascorbic and succinic acid. Haematologic response may be impaired when used w/ vit E. Antagonises the hypotensive effect of methyldopa. May reduce the absorption of penicillamine, bisphosphonates, fluoroquinolones, entacapone, mycophenolate, tetracyclines, Zn, levothyroxine, levodopa, carbidopa, nalidixic acid, eltrombopag. Neomycin may alter the absorption of Fe. Oral chloramphenicol delays plasma Fe clearance, incorporation into RBC and interferes w/ erythropoiesis.
Food Interaction
Delayed absorption w/ food esp coffee, eggs, milk, tea, whole grain breads and cereals.
Lab Interference
May interfere w/ tests used for detection of occult blood in stool.
Action
Description: Ferrous gluconate is used in the prevention and treatment of iron-deficiency anaemia. It replaces Fe found in Hb, myoglobin and enzymes. It also allows transportation of oxygen via Hb.
Onset: Haematologic response: 3-10 days.
Pharmacokinetics:
Absorption: Absorbed in the duodenum and proximal jejunum. Reduced absorption w/ food.
Distribution: Plasma protein binding: High.
Excretion: Via faeces, urine, breast milk, perspiration, menses, and shedding of hair, skin and nails.
Storage
Store between 20-25°C.
ATC Classification
B03AA03 - ferrous gluconate ; Belongs to the class of oral iron bivalent preparations. Used in the treatment of anemia.
References
Anon. Ferrous Gluconate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 28/02/2017 .

Buckingham R (ed). Ferrous Gluconate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com . Accessed 28/02/2017 .

Ferrous Gluconate Tablet (Paddock Laboratories, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 28/02/2017 .

Joint Formulary Committee. Ferrous Gluconate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com . Accessed 28/02/2017 .

Disclaimer: This information is independently developed by MIMS based on Ferrous gluconate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in